Invivyd Shares Climb on Positive Phase 3 COVID-19 Therapy Update

Shares of Waltham-based biotech firm Invivyd (IVVD) trended higher on Thursday after the company released an update regarding its late-stage clinical trial for a novel COVID-19 preventative therapy. The company is currently conducting the DECLARATION study, a Phase 3 pivotal trial designed to assess the effectiveness of its experimental candidate, VYD2311. The therapy is specifically engineered to prevent the onset of symptoms in patients exposed to the virus. According to an interim analysis of the study, Invivyd reported progress in the trial's objectives. While specific data points were not detailed in the immediate update, the positive trajectory of the pivotal study has bolstered investor confidence in the candidate's potential. The reaction in the equity markets reflects the high-stakes nature of Phase 3 trials in the biotechnology sector, where successful outcomes are critical for regulatory approval and subsequent commercialization. Investors are now looking toward the final results of the DECLARATION study to determine the therapy's viability for broader market use.